SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (3473)12/30/1997 3:54:00 PM
From: David S.  Read Replies (2) | Respond to of 6136
 
How about a tobacco blintz? mmmmmm. to be serious, I've spoken to many people, and come out with the opinion that...John W will hate this,,, Sustiva will take sales out of Viracept but also 3TC. I cannot quantify the degree of either. Other factors are degree of penetration of triple comb therapy, and many others, but Sustiva is just another unknown thrown into the mess. Uh oh, I better duck!
Yes, I know about the increase in Viracept blood level as a result of Sustiva.



To: Izzy who wrote (3473)12/31/1997 12:32:00 PM
From: Oliver & Co  Read Replies (1) | Respond to of 6136
 
<I was hoping that Thymitaq would be available to me, but I guess no such luck (altho' I think the clinical trials are still going on, and with some success)>

Izzi, is there a personal reason?, or you meant for use in your lung ca patients.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News